leisure time -WSS

leisure time

author：fashion 2025-10-01 00:46:53 - browse：7795

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Treeline, Josh Bilenker's next biotech, is cloaked in mystery

WSS

The biotech scorecard for Q4: 16 stock

What Henrietta Lacks settlement says about racism in medicine

Experts study whether long Covid risk adds up with each reinfection

Study points to new risk in gene therapy death of Terry Horgan

ProMED, early warning system on disease outbreaks, in peril

Verily hires former Apple Health leader as chief scientific officer

focus

leisure time

focus

How one medical school became remarkably diverse

Congress extends some pandemic preparedness programs

BioMarin wins approval for gene therapy to treat hemophilia A

ProMED, early warning system on disease outbreaks, in peril

Supreme Court strikes down use of affirmative action

What Henrietta Lacks settlement says about racism in medicine

Dobbs anniversary: the lost opportunity of abortion as health care

ER docs worry over extreme heat as a 'mass casualty event'

As demand for Covid shots wanes, Moderna seeks its next success

OTC birth control: A brief history of over the counter pill design

entertainment

WHO recommends second malaria vaccine

Health insurers' Q3 question: how much care are people getting?

CDC picks Alphabet's Verily for wasterwater surveillance contract

CDC picks Alphabet's Verily for wasterwater surveillance contract

Nearly two

A cyberattack has disrupted hospitals and health care in several states

entertainment

focus

focus

leisure time